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Background: Second-line chemotherapy treatment of patients with relapsed gastric and oesophageal cancers in comparison with
supportive care (SC) alone has been supported by recent phase 3 clinical trials, but a meta-analysis of patient-level data is lacking.
Methods: We searched Medline, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Web of Science for
phase 3 clinical trials that compared second-line chemotherapy with SC alone for gastric and oesophageal cancers. A meta-
analysis of the comprehensive patient-level data from the three identified trials was performed.
Results: A total of 410 patients with gastric (n¼ 301), gastroesophageal junction (n¼ 76), or oesophageal (n¼ 33) adenocarcinoma
were identified. In all, 154 patients received single-agent docetaxel and 84 patients received single-agent irinotecan, each with SC.
SC alone was given to 172 patients. Chemotherapy significantly reduced the risk of death (hazard ratio (HR)¼ 0.63, 95% confidence
interval (CI)¼ 0.51–0.77, Po0.0001). This effect was observed for treatment with docetaxel (HR¼ 0.71, 95% CI¼ 0.56–0.89,
P¼ 0.003) and irinotecan (HR¼ 0.49, 95% CI¼ 0.36–0.67, Po0.001). Overall survival (OS) benefit was greatest for patients who
progressed 3–6 months following first-line chemotherapy (HR¼ 0.39, 95% CI¼ 0.26–0.59, Po0.0001). Performance status (PS) 0–1
compared with PS 2 (HR¼ 0.66, 95% CI¼ 0.46–0.94, P¼ 0.02), locally advanced disease compared with metastatic disease
(HR¼ 0.41, 95% CI¼ 0.25–0.67, P¼ 0.0004) and older age (HR¼ 0.94 per 5 years, 95% CI¼ 0.90–0.99, P¼ 0.01) were significant
predictors of improved OS. Progression of disease during first-line treatment (HR¼ 1.24, 95% CI¼ 0.96–1.59) or within the first 3
months of completion of first-line treatment (HR¼ 1.42, 95% CI¼ 1.09–1.83) were predictors of an increased risk of death
compared with progression between 3 and 6 months (P¼ 0.03). Health-related quality of life outcomes were reported in only one
of the three trials, precluding meta-analysis of these parameters.
Conclusions: This meta-analysis of patient-level data confirms that second-line chemotherapy treatment results in significantly
better OS compared with SC alone in patients with platinum and fluoropyrimidine refractory gastric and oesphageal
adenocarcinoma. Health-related quality of life outcomes should be included in future trials in this setting.
*Correspondence: Dr T Janowitz; E-mail: tj212@cam.ac.uk or Dr A Marshall; E-mail: Andrea.Marshall@warwick.ac.uk or
Dr S Park; E-mail: hematoma@skku.edu
6These authors contributed equally to this work as first authors.
Received 24 August 2015; revised 11 November 2015; accepted 30 November 2015
& 2016 Cancer Research UK. All rights reserved 0007 – 0920/16
FULL PAPER
Keywords: gastric cancer; second-line chemotherapy; supportive care; meta-analysis; patient-level data; age
British Journal of Cancer (2016) 114, 381–387 | doi: 10.1038/bjc.2015.452
www.bjcancer.com |DOI:10.1038/bjc.2015.452 381
An evidence base for second-line treatment of gastric and
oesophageal cancers is important for the following reasons. First,
the global incidence rates are high with 989 000 gastric cancer and
482 000 oesophageal cancer cases yearly, ranking them as the
fourth and seventh most common cancer, respectively.(Ferlay et al,
2010) Second, most patients are diagnosed with locally advanced or
metastatic disease at which point median overall survival (OS) with
first-line chemotherapy is only approximately 7–11 months
(Wagner et al, 2010). Third, after first-line combination treatment
including surgery for early-stage disease, the majority of patients
relapse (Hartgrink et al, 2009). Consequently, gastric and
oesophageal adenocarcinoma claim more than a million lives
annually and contribute an estimated 15.1% to global cancer
mortality (Ferlay et al, 2010).
Three phase 3 randomised controlled clinical trials have
demonstrated superior OS with second-line irinotecan or docetaxel
chemotherapy compared with active symptom control or
best supportive care (SC) alone, hereafter referred to as SC
(Thuss-Patience et al, 2011; Kang et al, 2012; Ford et al, 2014).
A further phase 3 trial compared paclitaxel and irinotecan
chemotherapy without a SC arm and described similar OS for
both chemotherapies (Hironaka et al, 2013). Four phase 3 trials
have reported on targeted treatment in the same clinical setting.
Everolimus, a mammalian target of rapamycin inhibitor, did not
improve OS compared with placebo in patients with advanced
gastric cancer progressing after one to two lines of chemotherapy
(Ohtsu et al, 2013). Gefitinib, an EGFR inhibitor, provided
a 0.4 month benefit in progression-free survival and improvement
in a selection of health-related quality of life (HRQoL) outcomes,
but no OS benefit compared with placebo in patients with
oesophageal cancer progressing after up to three lines of
chemotherapy (Dutton et al, 2014). In contrast, ramucirumab, an
anti-vascular endothelial growth factor receptor type 2 antibody,
provided an OS benefit comparable to the benefit achieved with
chemotherapy (Fuchs et al, 2014). Ramucirumab has also
been shown to deliver a combination benefit with paclitaxel
chemotherapy when compared with single-agent paclitaxel (Wilke
et al, 2014).
To corroborate the evidence base for second-line treatment with
chemotherapy in gastric and oesophageal adenocarcinoma, we
performed a comprehensive meta-analysis of the patient-level data
of the three relevant phase 3 trials. A previous study has reported
preliminary meta-data on hazard ratios (HRs) from results that
were in one case incomplete and only published as conference
abstract (Kim et al, 2013). A second meta-analysis of second-line
treatment for gastric cancer, which included ramucirumab single-
agent treatment, was based only on trial-level data (Iacovelli et al,
2014). Our study provides several new results based on an in depth
analysis of patient-level data as well as the definitive results of the
meta-analysis, including the definitive results for OS.
MATERIALS AND METHODS
Study criteria, search, and selection. This meta-analysis follows
PRISMA guidelines (Moher et al, 2009). We included all completed
and peer review published phase 3 randomised clinical trials that
investigated the effect of second-line chemotherapy in comparison
with SC for the treatment of gastric and oesphageal adenocarci-
noma. We searched PubMed, the Web of Science, and the
Cochrane Central Register of Controlled Trials up to the date of 19
August 2015.
We used the search algorithm: clinical trial, phase 3 AND
(randomised OR randomised, controlled trial) AND (gastric OR
gastroesophageal OR oesophagogastric OR stomach) AND (cancer
OR neoplasm OR carcinoma OR malignant OR malignancy) AND
(second-line OR salvage OR supportive care OR active symptom
control) AND (chemotherapy OR chemotherapeutic OR anti-
neoplastic agent OR therapy). All identified entries were screened
for relevance, eligibility, and duplication.
Data collection and data items. The chief investigators and trial
groups of the three identified trials provided comprehensive
patient-level data from the original trial databases. Data were
sought for the primary outcome of OS as well as for the patient
characteristics of sex, age, and Eastern Cooperative Oncology
Group (ECOG) performance status (PS). Data on disease status,
site of primary disease, and response to previous chemotherapy
were collated and analysed as well as data on treatment, including
type of chemotherapy, number of administered cycles, reason for
end of treatment, best response to first-line chemotherapy, and
administration of further chemotherapy after trial participation.
Summary measures and statistical analysis. The primary out-
come of this meta-analysis was OS, calculated as the time from trial
entry until death from any cause or censored at the date last known
to be alive. Updated follow-up data were obtained compared
with the published data (Thuss-Patience et al, 2011; Kang et al,
2012; Ford et al, 2014) and therefore an analysis of the individual
trials was performed using Kaplan–Meier survival curves to obtain
the median survival and associated 95% confidence interval (CI)
using the log-log transformation. For illustration, a Kaplan–Meier
survival curve of all trials has been provided in the Supplementary
Figure 1. Because this is based on pooled data from the three trials
no HRs have been calculated and interpretation is limited (Tierney
et al, 2015). Heterogeneity between the studies was assessed using
the Cochran’s Q statistic (Early Breast Cancer Trialists’ collabora-
tive group 1990). A one-stage random effects model was used for
the analysis of the data.
The patient, disease, and treatment characteristics were
evaluated for their prognostic value of OS using a multivariable
one-stage random effects Cox proportional hazards model using
backwards regression.
Analyses were performed using the SAS statistical software
(version 9.3) and R statistical software (version 3.0.3). Results were
reported as HR with 95% CIs. Reported P-values were two sided,
had not been adjusted for multiple testing, and were considered
statistically significant at a value of less than 0.05.
Risk of bias. Clinical trials that had not published results in peer-
reviewed medical journals or were not randomised phase 3 trials
were not included in this meta-analysis. There is a risk that such
trials would have identified different effects on OS. Most smaller
studies, retrospective analysis, case series, and case reports,
however, indicate benefit of chemotherapy. Reports on such
smaller studies had already resulted in use of second-line
chemotherapy in patients with relapsed gastric and oesophageal
adenocarcinoma, before the establishment of level 1 evidence of OS
benefit by phase 3 clinical trials (Ford and Gounaris, 2015).
RESULTS
The database searches returned 32 entries in PubMed, 30 reports in
the Cochrane Register, and 75 entries in the Web of Science.
Twenty-nine were duplicate entries. The majority of these 108
identified publications had to be excluded because they were not a
randomised phase 3 trial, did not investigate second-line
chemotherapy vs SC in gastric and oesophageal cancers, or were
not peer reviewed. One phase 3 trial compared second-line
chemotherapy with paclitaxel against irinotecan without a SC arm
(Hironaka et al, 2013) and was, therefore, excluded. Three phase 3
trials compared targeted treatment with everolimus (Ohtsu et al,
2013), ramucirumab (Fuchs et al, 2014), or gefitinib with SC, but
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were excluded because they did not involve administration of
chemotherapy. The RAINBOW trial did not include a SC arm
(Wilke et al, 2014) and was consequently not included in this
analysis. Final manual assessment of all entries resulted in
identification of three phase 3 trials that fulfilled eligibility criteria
for this meta-analysis (Thuss-Patience et al, 2011; Kang et al, 2012;
Ford et al, 2014).
Study, patient, disease, and primary treatment characteristics.
The study, patient, disease, and primary treatment characteristics
for the 410 patients of the three individual trials are summarised in
Table 1. The trials had a higher proportion of patients who were
male compared with female (n¼ 302 vs n¼ 108), aged below 70
years compared with above 70 years (n¼ 348 vs n¼ 62), and who
had an ECOG PS of 0 or 1 compared with 2 (n¼ 373 vs n¼ 37).
The trial conducted by Ford et al (2014) was the only trial to
include locally advanced patients and therefore the majority of the
patients across the three trials had metastatic disease rather than
locally advanced disease (n¼ 389 vs n¼ 21). The largest of the
three trials, conducted by Kang et al, only included patients with
gastric cancer and overall more patients had gastric rather than
gastroesophageal junction or oesophageal cancers (n¼ 301 vs
n¼ 76 vs n¼ 33).
A higher proportion of patients had a complete response (CR)
or partial response (PR) to previous chemotherapy within the trial
reported by Kang et al compared with the others (Table 1). Overall,
most patients (n¼ 199, 49%) had progressive disease (PD) as their
best response to previous chemotherapy, 78 patients (19%) had
stable disease, 117 patients (29%) had PR, and 6 patients (1%) had
CR. A similar number of patients had progressed either during or
Table 1. Study, patient, disease, and primary treatment characteristics
Study characteristics
Ford et al (2014)
n (%)
Thuss-Patience
et al (2011)
n (%)
Kang et al (2012)
n (%) Total
Total patient enrolment 168 40 202 410
Treatment details Docetaxel 75mgm 2
every 3 weeks (n¼ 84)
vs SC (n¼84)
Irinotecan 250mgm2
cycle 1, thereafter up to
350mgm2 every 3 weeks
(n¼ 21) vs SC (n¼19)
Irinotecan 150mgm2 every
2 weeks (n¼63) vs Docetaxel
65mgm2 every 2 weeks
(n¼70) vs SC (n¼69)
Maximum number of cycles 6 10 12
Patient characteristics
Sex
Male 136 (81%) 29 (73%) 137 (68%) 302 (74%)
Female 32 (19%) 11 (22%) 65 (32%) 108 (26%)
Age, years (median (range)) 65 (28–84) 58 (35–73) 56 (31–76) 59 (28–84)
Age p70 129 (77%) 37 (93%) 182 (90%) 348 (85%)
Age 470 39 (23%) 3 (7%) 20 (10%) 62 (15%)
ECOG PS
0 or 1 142 (84%) 31 (78%) 200 (99%) 373 (91%)
0 46 (27%) – 108 (53%) 154
1 96 (57%) – 92 (46%) 188
2 26 (16%) 9 (22%) 2 (1%) 37 (9%)
Disease characteristics and previous treatment
Disease status
Locally advanced 21 (13%) 0 0 21 (5%)
Metastatic disease 147 (87%) 40 (100%) 202 (100%) 389 (95%)
Site of primary disease
Oesophagus 33 (20%) 0 0 33 (8%)
Oesophago-gastric junction 59 (35%) 17 (42%) 0 76 (18%)
Stomach 76 (45%) 23 (58%) 202 (100%) 301 (73%)
Response to previous CT
CR 0 2 (5%) 4 (2%) 6 (1%)
PR 29 (17%) 9 (22%) 79 (39%) 117 (29%)
SD 42 (25%) 10 (25%) 26 (13%) 78 (19%)
PD 91 (54%) 19 (48%) 89 (44%) 199 (49%)
Non-evaluable 6 (4%) 0 4 (2%) 10 (2%)
Time between end of previous CT and documented PD
During treatment 72 (43%) 16 (40%) 74 (37%) 162 (39%)
Within 3 months 49 (29%) 19 (48%) 75 (37%) 143 (35%)
3–6 Months 47 (28%) 5 (12%) 53 (26%) 105 (26%)
Number of sites of PD
1 65 (39%) 17 (42%) 70 (35%) 152 (37%)
2 or more 103 (61%) 23 (58%) 132 (65%) 258 (63%)
Previous surgery
No 127 (76%) 20 (50%) 158 (78%) 305 (74%)
Yes 41 (24%) 20 (50%) 44 (22%) 105 (26%)
Previous radiotherapy
No 157 (93%) 40 (100%) 172 (85%) 369 (90%)
Yes 11 (7%) 0 30 (15%) 41 (10%)
Abbreviations: CR¼ complete response; PD¼progressive disease; PR¼partial response; PS¼performance status; SD¼ stable disease.
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within 3 or 3–6 months of previous chemotherapy across the three
trials. Most patients did not receive treatment in the form of
surgery (n¼ 305 vs n¼ 105) or radiotherapy (n¼ 369 vs n¼ 41)
before enrolment.
Second-line chemotherapy and SC treatment. The data relating
to trial treatments analysed in this meta-analysis are listed in
Table 2. Out of the 238 patients who were allocated to
chemotherapy plus SC across the three trials, 154 patients received
docetaxel and 84 irinotecan. A total of 866 cycles of chemotherapy
were administered with a median of three cycles per patient
(range 0–12). Most patients stopped treatment because of PD
(n¼ 165, 69%), followed by unacceptable toxicity (n¼ 24, 10%),
and completion of treatment (n¼ 19, 8%). No case of CR was
observed, but 15 patients (6%) had PR, and 75 patients (32%) had
stable disease. PD was the best response to chemotherapy in 116
patients (49%).
Assessment of patients on both arms was scheduled at the same
frequency in all included trials (Supplementary Table 1). Both arms
allowed management of symptoms with analgesia, anti-emetics,
steroids, and palliative radiotherapy. Subsequent chemotherapy
was permitted in both treatment arms. After trial completion,
97 (24%) of the entire 410 patients (24%) received further
chemotherapy: 65 (27%) of the 238 patients allocated to
chemotherapy plus SC, 32 (19%) of the 172 patients on the SC
arms (Supplementary Table 2).
Treatment effect on OS. Each of the three trials had a significant
reduction in the HR for death and an increased median survival of
approximately 2 months with chemotherapy and SC compared
with SC alone (Table 3). A Kaplan–Meier curve of patient survival
data across all trials is presented in Supplementary Figure 1.
Meta-analysis with a one-stage random effects Cox regression
model confirmed a highly significant reduction in the risk of death
Table 2. Chemotherapy and disease response characteristics
Kang et al (2012)
Chemotherapy details
Ford et al
(2014)
n (%)
Thuss-Patience
et al (2011)
n (%)
Total,
n (%)
Docetaxel arm,
n (%)
Irinotecan arm,
n (%)
CTþSC 84 21 133 70 63
CT type
Docetaxel 84 (100%) 0 70 (51%)
Irinotecan 0 21 (100%) 63 (47%)
Number of cycles administered
0 7 (8%) 2 (10%) 2 (2%) 1 (1%) 1 (2%)
1 17 (20%) 2 (10%) 20 (15%) 11 (16%) 9 (14%)
2 10 (12%) 7 (33%) 29 (22%) 20 (29%) 9 (14%)
3 23 (27%) 2 (10%) 23 (17%) 13 (19%) 10 (16%)
4 5 (6%) 2 (10%) 10 (8%) 4 (6%) 6 (10%)
5 3 (4%) 3 (14%) 6 (5%) 1 (1%) 5 (8%)
6 19 (23%) 1 (5%) 22 (17%) 13 (19%) 9 (14%)
46 0 2 (10%) 21 (16%) 7 (10%) 14 (22%)
Total number of cycles 255 68 543 243 300
Median number of cycles (range) 3 (0–6) 2 (0–9) 3 (0–12) 3 (0–9) 4 (0–12)
Reason for treatment ending
Completion of treatment 19 (23%) 0 0 0 0
Unacceptable toxicity 20 (24%) 2 (10%) 2 (1%) 2 (3%) 0
Treatment delay 421 days 5 (6%) 0 1 (1%) 1 (1%) 0
Progressive disease 26 (31%) 13 (62%) 126 (95%) 67 (96%) 59 (94%)
Treatment refused by patient 1 (1%) 1 (5%) 4 (3%) 0 4 (6%)
Patient died 10 (12%) 2 (10%) 0 0 0
Other 3 (4%) 3 (14%) 0 0 0
Best response to CT
Partial response 4 (5%) 0 11 (8%) 6 (9%) 5 (8%)
Stable disease 26 (31%) 10 (48%) 39 (29%) 18 (26%) 21 (33%)
Progressive disease 24 (29%) 11 (52%) 81 (61%) 46 (66%) 35 (56%)
Non-evaluable/not assessed 30 (36%) 0 2 (2%) 0 2 (3%)
Abbreviations: CT¼ chemotherapy; SC¼ supportive care.
Table 3. Summary of OS and hazard ratios
Survival
Ford et al (2014)
n (%)
Thuss-Patience et al (2011)
n (%)
Kang et al (2012)
n (%)
Total patient enrolment 168 40 202
Number of events 165 40 202
Median survival (95% CI)
CTþSC 5.2 (4.1–5.9) 4.0 (2.6–5.6) 6.3 (5.0–7.2)
SC 3.6 (3.3–4.4) 2.4 (1.2–3.5) 3.7 (2.7–4.5)
Hazard ratio (95% CI) 0.72 (0.53–0.98) 0.48 (0.25–0.92) 0.58 (0.43–0.78)
P-value (two sided) 0.04 0.02 0.0003
Abbreviations: CI¼ confidence interval; CT¼ chemotherapy; OS¼overall survival; SC¼ supportive care.
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for patients receiving chemotherapy and SC compared with SC
alone (HR¼ 0.63, 95% CI¼ 0.51–0.77, Po0.0001, Figure 1). This
effect was confirmed for chemotherapy use with docetaxel
(HR¼ 0.71, 95% CI¼ 0.56–0.89, P¼ 0.003) and irinotecan
(HR¼ 0.49, 95% CI¼ 0.36–0.67, Po0.0001, Figure 2).
Treatment interactions. The interaction between time to pro-
gression (TTP) and treatment is the only significant treatment
interaction (P¼ 0.04, Table 4), suggesting that the treatment effect
was similar across all other covariate subgroups. Patients
progressing within 3–6 months after prior chemotherapy tended
to have more benefit from second-line chemotherapy (HR¼ 0.39,
95% CI¼ 0.26–0.59, Po0.0001) than those who progressed
within 3 months of completing treatment (HR¼ 0.70, 95%
CI¼ 0.49–0.99, P¼ 0.04) or during treatment (HR¼ 0.75, 95%
CI¼ 0.54–1.04, P¼ 0.08).
Predictors of OS. In a multivariable one-stage random effects Cox
regression model, PS (P¼ 0.02), disease stage (P¼ 0.0004), TTP
after first-line chemotherapy (P¼ 0.03), and age (P¼ 0.01) were all
significant predictors of OS in addition to treatment (Po0.0001).
Patients with a PS of 0–1 compared with PS 2 (HR¼ 0.66, 95%
CI¼ 0.46–0.94), or locally advanced disease compared with
metastatic disease (HR¼ 0.41, 95% CI¼ 0.25–0.67) or older age
(HR¼ 0.94 per 5 years, 95% CI¼ 0.90–0.99) had an improved OS.
In contrast, patients whose disease progressed during first-line
treatment (HR¼ 1.24, 95% CI¼ 0.96–1.59) or within the first 3
months of completion of first-line treatment (HR¼ 1.42, 95%
CI¼ 1.09–1.83) were more likely to have shorter OS than those
who progressed 3–6 months after first-line treatment completion.
DISCUSSION
Three phase 3 trials have reported a significantly improved OS
with second-line chemotherapy and SC compared with SC alone
(Thuss-Patience et al, 2011; Kang et al, 2012; Ford et al, 2014).
HR and 95% CI (CT+SC : SC)
HR and 95% CI (CT+SC : SC)
0.72 (0.53–0.98)
0.48 (0.25–0.92)
0.58 (0.43–0.78)
0.63 (0.51–0.77)
(P<0.0001)
CT + SC better SC better
Heterogeneity between 3 groups: 2=2.2, P=0.33
Ford et al. 2014
Kang et al. 2012
Overall
Thuss-Patience et al. 2011
0 0.5 1.51 2
Trial
Figure 1. Forest plot of the hazard ratio (HR) for death of chemotherapy and supportive care (CTþ SC) compared with supportive care (SC)
alone. Overall HR from a one-stage random effects Cox regression model.
Docetaxel
Ford et al. 2014
Kang et al. 2012
Stratified
Interaction between 2 groups: 2=0.0, P= 0.85
Interaction between 2 groups: 2=0.0, P= 0.88
Irinotecan
Thuss-Patience et al. 2011
Kang et al. 2012
Stratified
Overall
0 0.5 1.51 2
CT + SC better SC better
HR and 95% CI (CT+SC : SC)
0.72 (0.53–0.98)
0.69 (0.49–0.97)
0.71 (0.56–0.89)
0.48 (0.25–0.92)
0.50 (0.35–0.71)
0.49 (0.36–0.67)
0.63 (0.51–0.77)
(P< 0.0001)
(P< 0.0001)
(P= 0.003)
HR and 95% CI (CT+SC : SC)
Figure 2. Forest plot of the hazard ratio (HR) for death with chemotherapy and supportive care (CTþ SC) compared with supportive care (SC)
alone for trials using docetaxel and those using irinotecan separately. Overall HR from a one-stage random effects Cox regression model.
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This meta-analysis examined patient-level data from these three
trials. It definitively confirms highest level evidence of an OS
benefit with second-line chemotherapy (HR¼ 0.63, 95%
CI¼ 0.51–0.77, Po0.0001). Overall survival benefit is conferred
by both docetaxel (HR¼ 0.71, 95% CI¼ 0.56–0.89, P¼ 0.003) and
irinotecan (HR¼ 0.49, 95% CI¼ 0.36–0.67, Po0.0001). These
findings consolidate the use of second-line chemotherapy as the
standard of care in the management of relapsed gastric and
oesphageal adenocarcinoma.
Future clinical trials are required to further improve the
outcome for patients with gastric and oesophageal adeno-
carcinoma. Targeted therapies have shown some promise in recent
phase 3 trials. Ramucirumab, a monoclonal antibody targeting
vascular endothelial growth factor receptor type 2, increases
median OS in relapsed gastric cancer, both as a single-agent
relative to placebo in the REGARD trial (Fuchs et al, 2014) and in
combination with paclitaxel relative to single-agent paclitaxel in
the RAINBOW trial (Wilke et al, 2014). In contrast, everolimus,
for patients progressing after chemotherapy for advanced gastric
cancer, did not confer an OS benefit (Ohtsu et al). Gefitinib, for
patients progressing after chemotherapy for oesophageal cancer,
while not conferring an OS benefit, was associated with an
improvement in aspects of HRQoL outcomes, including odyno-
phagia, and notable rapid and durable responses in a subpopula-
tion of patients (Dutton et al, 2014). Preliminary data from a
phase 2 study, communicated in a conference abstract,
indicate significant improvement in progression-free survival with
regorafenib, a multi-kinase inhibitor, in patients with relapsed
gastric and oesophageal cancer (Pavlakis et al, 2015). Final data are
awaited. In summary, to date, current gains in OS with second-line
agents, including combination regimes, remain modest.
Identification of biomarkers or clinical data predictive of patient
response to therapy will help select those most likely to benefit
from treatment. This meta-analysis has identified TTP after
first-line chemotherapy to impact significantly on response to
second-line chemotherapy: patients progressing 3–6 months
following first-line chemotherapy gained most benefit in OS,
whereas there was no significant gain in OS for those patients who
progressed during first-line chemotherapy. This finding warrants
stratification by TTP from first-line chemotherapy in future studies
evaluating second-line chemotherapy and prospective evaluation
with other treatment agents and combinations. In contrast, an
effect on OS between progression-free interval of less than vs more
than 6 months was not found with ramucirumab in the REGARD
study (Fuchs et al, 2014). Thus, clinical data predictive of response
may vary between chemotherapy and targeted therapy and should
be considered in both treatment and patient selection and be
examined in more detail in trials of second-line therapy.
This meta-analysis has identified an OS benefit from second-
line chemotherapy independent of age. Indeed, older age has been
found to be a positive predictor of improved OS with second-line
chemotherapy (HR¼ 0.94 per 5 years, 95% CI¼ 0.90–0.99). These
findings, not previously reported in this setting, are of particular
relevance for routine clinical practice considering the association of
age with poor prognosis and increased cancer-specific mortality in
patients with gastric cancers (Yang et al, 2011; Koppert et al, 2012).
Furthermore, older age has, in some cases, been an exclusion
criterion for trials in this setting (Thuss-Patience et al, 2011;
Hironaka et al, 2013; Fuchs et al, 2014). The data from this meta-
analysis suggest patients of older age have greater potential gain
from second-line treatment and, consequently, their inclusion in
future trials should be considered.
In a population vulnerable to both disease- and treatment-
associated impacts on quality of life, future trials should include
HRQoL outcomes to confirm improved OS is not achieved at the
expense of reduced HRQoL. Of the phase 3 trials comparing
second-line chemotherapy to SC, only Ford et al reported detailed
HRQoL, and found no deterioration in global HRQoL and,
furthermore, a reduction in pain with docetaxel and SC compared
with SC alone (Ford et al, 2014). The REGARD and RAINBOW
trials similarly found no adverse impact on global quality of
life in treatment vs control arms. However, although at least
90% of patients completed baseline questionnaires in these
studies, the proportion of patients completing questionnaires
after 6 weeks of initiating treatment declined dramatically (Fuchs
et al, 2014; Wilke et al, 2014). Overcoming the challenges of
nonresponse will be important in the adequate assessment of
quality of life.
The use of SC as a comparator arm in clinical trials requires
effective definition and delivery to ensure validity. Across the three
trials, patients in SC and SC plus chemotherapy arms were assessed
with similar frequency, with attention given to both assessment
and symptom management, conforming to consensus guidelines
(Zafar et al, 2012). A potential limit to the general applicability of
this meta-analysis is the median age of 59 years, younger than in
the regular clinical population. However, this study is not limited
by incomplete data retrieval and was informed by patient-level data
of all three phase 3 trials. It therefore provides definitive guidance
on the treatment of gastric and oesophageal adenocarcinoma with
single-agent second-line chemotherapy. We note that similar HRs
for OS with overlapping CI to this meta-analysis were published in
a previous trial-level meta-analysis (Kim et al, 2013). The authors
noted, however, that clinical and pathology data were not analysed
and the outcome data for one of the trials were only reported in
form of a conference abstract. Another meta-analysis, limited by
the use of clinical trial-level data and inclusive of ramucirumab
single agent treatment, reported similar results (Iacovelli et al,
2014). Although we largely agree with the discussion in both
preliminary meta-analyses, we believe that a meta-analysis of
phase 3 trials should be informed by the highest quality data at
patient-level.
In conclusion, this meta-analysis demonstrates that second-line
chemotherapy with docetaxel or irinotecan improves OS in gastric,
gastroesophageal junction, and oesophageal cancers compared with
SC alone. The wealth of evidence for efficacy of second-line
treatment compared with SC, substantiated by this meta-analysis,
confirms that second-line chemotherapy should be considered the
standard of care. Future clinical trials in this setting should no
longer consider SC an adequate control arm.
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Table 4. Treatment by covariate interactions in a one-stage
random effects Cox regression model for OS
Parameter
P-value for treatment
by covariate
interaction term
Age 0.34
Gender (male vs female) 0.88
Performance status (0 or 1 vs 2) 0.44
Disease stage (locally advanced vs metastatic) 0.18
TTP from first-line chemotherapy (during treatment
vs within 3 months vs within 3–6 months)
0.04
Disease site (oesophagus vs OG junction vs stomach) 0.28
Number of progression sites (1 vs 2 or more) 0.28
Abbreviation: TTP¼ time to progression.
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